Start your patients on KISQALI with confidence
.
SIMPLIFIED TREATMENT INITIATION
A few standard assessments help to ensure your patients start right away
- Complete blood count (CBC)1
- Liver function tests (LFTs)1,*
- Electrolyte levels1,†
- Electrocardiogram (ECG)1,‡
Straightforward ECG testing
- The 2 required ECGs are both completed within the first 2 weeks of treatment1
- If you are unable to perform ECGs in office, speak with your Novartis Oncology Specialist about a simple solution for fast, easy, and accurate ECG testing
*Monitor LFTs prior to the initiation of treatment, every 2 weeks for the first 2 cycles, at the beginning of each of the subsequent 4 cycles, and as clinically indicated. For LFTs, if grade ≥2 abnormalities are noted, more frequent monitoring is recommended.1
†Monitor serum electrolytes prior to the initiation of treatment, at the beginning of the first 6 cycles, and as clinically indicated. Correct any electrolyte abnormalities before initiating treatment.1
‡KISQALI should only be initiated in patients with QTcF <450 ms.1
Additional monitoring may be required as clinically indicated.
Incidence of QT prolongation observed with KISQALI was low
Among cases of QT prolongation1:
0.3% had a >500 ms postbaseline QTcF value
2% had a >60 ms increase from baseline in QTcF interval
There were no reported cases of torsades de pointes
DOSING & ADJUSTMENTS
For your patients with stage II/III HR+/HER2- eBC,
Start with KISQALI 400 mg—the starting dose chosen to reduce both the risk of recurrence and dose-dependent ARs
KISQALI single-strength tablets make dose reduction simple and convenient1
KISQALI is given as 400 mg (2 x 200-mg tablets) orally, once daily (3 weeks on, 1 week off) for 36 months with an AI
Review the full Prescribing Information for recommended dosing of selected AI
An LHRH agonist should be used concomitantly with AI in men and premenopausal women
Patients should continue treatment for 3 years or until disease recurrence or unacceptable toxicity
Dose adjustments for adverse reactions should be made by reducing the number of tablets taken. Dose modification of KISQALI is recommended based on individual safety and tolerability. If dose reduction below 200 mg/day is required, discontinue treatment.
In the NATALEE trial, iDFS benefit was maintained for patients who required KISQALI dose reduction to manage ARs
NATALEE was a randomized, multicenter, open-label, phase III study of KISQALI + letrozole or anastrozole (n=2549) vs letrozole or anastrozole (n=2552) for the adjuvant treatment of men and women with stage II/III HR+/HER2- eBC. At a median follow-up of 33.3 months, with 509 iDFS (primary end point) events in the study (226 [8.9%] in the KISQALI arm and 283 [11.1%] in the NSAI-alone arm), iDFS at the 3-year landmark was 90.7% for KISQALI + NSAI vs 87.6% for NSAI alone (absolute difference 3.1%); there was a 25.1% relative reduction in the risk of an iDFS event; HR=0.749 (95% CI: 0.628-0.892).1,2
NOVARTIS PATIENT SUPPORT
A dedicated team for you and your patients
Novartis Patient Support™ is a comprehensive program that is designed to help your eligible patients start, stay, and save on KISQALI.
Your practice and patients will have access to a Novartis Patient Support team committed to providing the support you need, including:
Dedicated assistance with access and reimbursement
Assistance with relevant savings options for your eligible patients
Personalized support for your patients on therapy
Single points of contact for you and your patients